Jonathan Chang

MacroGenics Inc (NASDAQ: MGNX) reported Tuesday after the close with forecast-beating first-quarter results and said it has adequate cash to operate into 2022. The company also issued an update on its clinical pipeline. The MacroGenics Analyst SVB Leerink analyst Jonathan Chang reiterated an...

Tesla Inc (NASDAQ: TSLA)’s five-year general counsel stepped down this December after a high-pressure year of government scrutiny and class action lawsuits. Now, two months later, his replacement has already had enough. What Happened Dane Butswinkas decided Tesla wasn’t the right...

The Street is making up its mind on May’s market newbies, and ASLAN PHARMACEUTICALS ADR REP 5 ORD (NASDAQ: ASLN) received its judgment Wednesday. Two analysts issued Buy ratings and one a Market Perform. Here are the details on the more bearish thesis.  The Rating Leerink analyst...

ARMO Biosciences Inc (NASDAQ: ARMO)'s lead product candidate AM0010 is a drug for the treatment of pancreatic ductal adenocarcinoma recently showed "promising" data that's supportive of a potentially large commercial opportunity, according to Leerink. The Analyst Leerink's...

Shares of bluebird bio Inc (NASDAQ: BLUE) are up 360 percent over the last two years, but Leerink said the stock’s losing steam. The Rating Leerink analyst Michael Schmidt downgraded Bluebird from Outperform to Market Perform and increased the price target from $162 to $194. The Thesis...

Leerink downgraded shares of Exelixis, Inc. (NASDAQ: EXEL) and lowered its price target, citing an $8.6 billion diluted market cap. The firm thinks the consensus estimates now adequately reflect the commercial potential for Cabometyx in renal cell carcinoma, and the valuation implied additional...

Mirati Therapeutics, Inc. (NASDAQ: MRTX) shares are skyrocketing Friday in reaction to its announcement of positive preliminary data from two ongoing clinical trials of its non-small cell lung cancer, or NSCLC, candidate sitravatinib. The company said the data will be presented at the IASLC 2017...

Following Array Biopharma Inc (NASDAQ: ARRY) reporting positive top line results from part 2 of a late-stage study of its combo treatment candidate for metastatic and BRAF-mutant melanoma, Leerink thinks it will require a sizeable commercial effort to capture share in a market that has plateaued...

On Monday, Leerink issued a report previewing the American Society of Hematology annual meeting, which will be held from December 5 to December 8. Leerink believes that this meeting will have meaningful clinical updates for Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Juno Therapeutics Inc (...